Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foghorn TherapeuticsFHTX -2.19%67 Cash-to-Debt is 3.89 as of Jun. 2026, which is 30% below its 10-year median of 5.52. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,332 Biotechnology companies, Foghorn Therapeutics ranks worse than 59.23% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Foghorn Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.89.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Foghorn Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Foghorn Therapeutics's Cash-to-Debt or its related term are showing as below:
FHTX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.56 Med: 5.52 Max: 8.38
Current: 3.89
During the past 8 years, Foghorn Therapeutics's highest Cash to Debt Ratio was 8.38. The lowest was 0.56. And the median was 5.52.
FHTX's Cash-to-Debt is ranked worse than 59.23% of 1332
companies
in the Biotechnology industry
Industry Median: 7.355
vs FHTX: 3.89
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Foghorn Therapeutics Cash-to-Debt Related Terms
Foghorn Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Foghorn Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Foghorn Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics (FHTX) has a Cash-to-Debt of 3.89 as of Jun. 2026. This is 30% below median its historical median of 5.52. Over the past decade, Foghorn Therapeutics' Cash-to-Debt has ranged from 0.56 to 8.38. According to the industry distribution chart, Foghorn Therapeutics ranks #789 out of 1332 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Foghorn Therapeutics' Cash-to-Debt too high?
Foghorn Therapeutics' current Cash-to-Debt of 3.89 is 30% below median its 10-year median of 5.52. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 8.38. The Biotechnology industry median Cash-to-Debt is 7.36. Foghorn Therapeutics' value of 3.89 is 47.1% below this industry median. Based on the distribution chart, Foghorn Therapeutics ranks #789 out of 1332 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Cash-to-Debt compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #789 out of 1332 companies for Cash-to-Debt. This places Foghorn Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 7.36. Foghorn Therapeutics' value of 3.89 is 47.1% below this benchmark. Historically, Foghorn Therapeutics' own Cash-to-Debt has ranged from 0.56 to 8.38 over the past decade. While the company's 10-year median is 5.52 vs. the industry median of 7.36, Foghorn Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.36, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foghorn Therapeutics's current Cash-to-Debt of 3.89 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current Cash-to-Debt is 3.89, which is 30% below median its own 10-year median of 5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.68 — trading 25.5% above its estimated fair value. The current Cash-to-Debt is 3.89, which is 30% below median its 10-year median of 5.52 and 47.1% below the Biotechnology industry median of 7.36. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Cash-to-Debt is 3.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued.
The current stock price of $6.68 is trading 25.5% above its estimated GF Value™ of $5.32.
GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.
Key valuation signals for FHTX:
Cash-to-Debt: 3.89 (30% below median its 10-year median of 5.52)
GF Value™: $5.32 vs. price of $6.68 (25.5% above fair value)
Industry Position: 47.1% below the Biotechnology median (#789 of 1332)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score
Get the complete analysis for FHTX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
